跳转至内容
Merck
CN

SBR00029

Dansyl labeled polymyxin B

Ready Made Solution, for fluorescent microbial imaging, 1.5 mg/mL in H2O

别名:

DSL-PMB, DSL-PMX, DSL-PxB

登录 查看组织和合同定价。

选择尺寸

变更视图

关于此项目

NACRES:
NA.76
UNSPSC Code:
51102829
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助


Quality Level

form

ready-to-use solution

availability

not available in China

concentration

1.5 mg/mL in H2O

color

colorless to light brown

suitability

suitable for (Fluorescent detection of gram-negative bacteria), suitable for (Microbiome), suitable for microbiology

mode of action

cell membrane

shipped in

ambient

storage temp.

−20°C

General description

Dansyl Polymyxin B (DSL-PMB) is a fluorescent derivative of Polymyxin B. Polymyxin B is a cationic lipopeptide antibiotic that binds specifically to Gram-negative bacteria. Fluorescent antibiotics are obtained by synthetic conjugation of an antibiotic to a fluorophore.
Dansyl labeled Polymyxin B can be utilized for fluorescent microbial imaging in the fields of Cell Biology and Biochemical research.

Application

DSL-PMB may have been used:
  • as a fluorescent probe to study polymyxin mode of action and its pharmacokinetics
  • in research and to develop new active derivatives of Polymyxin against multi-drug resistance Gram-negative infections
  • to measure LPS binding affinity by fluorometric displacement assay
Fluorescent antibiotics can be used for many applications including:
  • Antimicrobial resistance research.
  • Bacterial visualization and imaging.
  • Parent antibiotic mode of action research and new antibiotic discovery.
  • Toxicity studies.
  • Research of bacterial infections and tracking its uptake in vivo.

Biochem/physiol Actions

DSL-PMB′s mode of action is in accordance with Polymyxin B activity. However, MIC assays comparing DSL-PMB, and parent Polymyxin B showed a two to three-fold decrease in bacterial activity. Polymyxin B interacts with anionic lipopolysaccharide (LPS) molecules which are located in Gram-negative bacterial outer membrane. This interaction interferes with the outer membrane′s normal function, causing leakage and enhanced uptake of the antibiotic. The resemblance in properties between Polymyxin B and DSL-PMB allows to fluorescently label Gram-negative bacteria and examine intracellular localization and penetration of Polymyxins in Gram-negative bacteria.

Features and Benefits

  • High-quality antibiotic suitable for multiple research applications
  • Ideal for Cell Biology, Metabolomics, and Biochemical research.

Analysis Note

  • Dansyl Labeled Polymyxin B Ready Made Solution is light sensitive.
  • It is recommended to avoid freeze-thaw cycles of PMB-DSL Ready Made Solution.
  • Dansyl Labeled Polymyxin B Ready Made Solution (1.5 mg/mL) can be diluted 1:50 in PBSX1 (Sigma#D8537) to achieve 30 μg/mL final concentration for staining. The above concentration of DSL-PMB was used for E. coli staining see image.
  • Fluorescence Microscopy application: Dansyl Labeled Polymyxin B Ready Made Solution excitation (Ex) wavelength is 330-340nm resulting in emission (Em) range of 540-600nm (λmax=570nm).

Other Notes

For additional information on our range of Biochemicals, please complete this form.


存储类别

12 - Non Combustible Liquids

法规信息

涉药品监管产品

此项目有



历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库



R A Moore et al.
Antimicrobial agents and chemotherapy, 30(6), 923-926 (1986-12-01)
Pseudomonas cepacia was found to be resistant to the outer membrane-permeabilizing effects of aminoglycoside antibiotics, polymyxin B, and EDTA. Permeabilization of P. cepacia to the fluorescent probe 1-N-phenylnaphthylamine was not achieved at concentrations 100- to 1,000-fold above those required to
P R Schindler et al.
Antimicrobial agents and chemotherapy, 8(1), 95-104 (1975-07-01)
Though the primary action of the cationic antibiotic polymyxin B is against the membrane of susceptible bacteria, severe morphological changes are detected in the cytoplasm. Using fluorescence microscopy and a mono-N-dansyl-polymyxin B derivative, we could demonstrate aggregations of the antibiotic
Vincent H Tam et al.
Antimicrobial agents and chemotherapy, 49(9), 3624-3630 (2005-08-30)
Despite limited data, polymyxin B (PB) is increasingly used clinically as the last therapeutic option for multidrug-resistant (MDR) gram-negative bacterial infections. We examined the in vitro pharmacodynamics of PB against four strains of Pseudomonas aeruginosa. Clonal relatedness of the strains



全球贸易项目编号

货号GTIN
SBR00029-1ML04061842638451